One of the flagship clinical trials of checkpoint inhibitors in metastatic melanoma, which established the combination of nivolumab and ipilimumab as a standard of care, has also provided the first report of melanoma-specific survival (MSS). A post hoc analysis of CheckMate-067 has reported the median MSS was not reached with combination treatment, compared to 58.7 ...
CheckMate-067: does long-term survival mean a new outcome measure for immunotherapy?
By Mardi Chapman
6 Dec 2021